Alector, Inc. develops investigational therapies for neurodegenerative diseases using an immuno-neurology approach informed by human genetics, neuroscience, and immunology. Its pipeline candidates are designed to remove toxic proteins, replace deficient proteins, or restore immune and nerve cell function in the brain, with programs targeting Alzheimer’s disease, frontotemporal dementia, ALS, and Parkinson’s disease. Biomarker-supported development helps focus on genetically defined patient populations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 3.7 | — | -40.5 | — |
| Q2 2025 | 7.9 | — | -30.5 | — |
| Q3 2025 | 3.3 | — | -34.7 | — |
| Q4 2025 | 6.2 | — | -37.3 | — |
| Q1 2026 | 1.1 | -71.5% | -22.9 | — |
| Q2 2026 | 3.3 | -57.8% | -23 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: SC II Acquisition Corp. (SCII), Immersion Corporation (IMMR), Virginia National Bankshares Corporation (VABK), Outdoor Holding Company (POWW), Velos Acquisition I Corp. (VLOS), Neumora Therapeutics, Inc. (NMRA)